EMDR Flash Forward as an intervention on the mental images of worst case scenarios in paranoid delusions

Phase 2

Recruiting

Conditions: Paranoid delusions
suspicious anxiety
10039628

Registration Number: NL-OMON52712

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Trial ended prematurely

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

1. The participants have been diagnosed with schizophrenia spectrum disorder,
with paranoid delusions as a core symptom (DSM-V).
2. A score on the Psyrats DRS of> 15.
3. The age must be between 16 and 60 years.
4. Prescribed medication for the treatment of psychosis must be stable for at
least a month.
5. A comorbid diagnosis of PTSD must have been treated adequately and symptoms
must be in remission.

Exclusion Criteria

1. Participants who still have to be adjusted to appropriate antipsychotic
medication.
2. Participants with serious dissociative symptoms.
3. Participants with an alcohol or substance dependency
4. Participants with organic syndrome, learning disability, or severe visual
impairments.
5. Participants who are already following a different psychological treatment
aimed at delusions.
6. Participants who have insufficient understanding of the Dutch language.
7. Participants who are suicidal.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary studyparameter is the Psychotic Symptoms, Delusion Rating Scale<br /><br>(Psyrats DRS), where it is expected that the (negative) difference score on the<br /><br>Psyrats DRS between start waiting list and end waiting list will be lower than<br /><br>between start treatment and end treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The Safety Behavior Questionnaire (SBQ) is administered, whereby it is expected<br />that the score on the SBQ at the start of the waiting list will be higher than<br />at the end of the treatment and even higher at the follow-up.</p>